Growth stocks copped it on Friday the 13th, as a Wall Street wobble triggered a fierce sell-off in tech and healthcare while money sprinted into utilities.

ASX uranium stocks suffered a vicious sell off earlier this month, but fundamentals suggest the pullback won't last, says ...

As miners line up to report their half-year profits, fundies still think gold producers are undervalued at home and abroad.

Rare diseases affect only a small number of people yet have become an attractive target for ASX healthcare companies.

Euroz Hartleys considers Broken Hill Mines (ASX:BHM) to be a speculative buy with a $1.87 price target ahead of silver ...

Justin sits down with Jeremy Pell, Country Manager ANZ at Elastic, the global Search AI company underpinning digital ...

A plunge in metal prices took its toll on resources stocks but KalGold and Talonx bucked the trend with high-grade gold results.

Blue chip giants potentially vulnerable to AI disruption insist that the tech is an enabler and not the enemy. Investors remain unconvinced.

Along with CSL, Pro Medicus has fallen victim to high investor expectations in a difficult climate for healthcare stocks.

ASX Healthcare lost 12% for week ending February 13, 2026 as Morgans' Scott Power said "it's brutal in the trenches" this reporting season.

The ASX 200 pushed to record highs as ANZ and Origin lifted banks and utilities, even as earnings season punished laggards.

A rival re-emerges, investors brace for impact and the Ozempic scare dissolves. ResMed’s growth story just got more interesting.